Navigation Links
Megan Dunbar Named VP of Programs for Pangaea Global AIDS Foundation
Date:3/18/2010

Pangaea Global AIDS Foundation today announced that Dr Megan Dunbar has been appointed Vice President of Programs and will join the organization on April 5. Pangaea Global AIDS Foundation helps countries, heavily affected by HIV, and their international partners, strengthen comprehensive prevention and treatment strategies, with a particular focus on hard-to-reach vulnerable populations, including women and girls, men who have sex with men, injecting drug users and incarcerated populations.

(PRWEB) March 18, 2010 -- Pangaea Global AIDS Foundation today announced that Dr Megan Dunbar has been appointed Vice President of Programs and will join the organization on the 5th of April.

Megan Dunbar, DrPH, has been a Prevention Consultant at Pangaea for several years and is a leader in global HIV prevention, care and treatment efforts focused on women and youth. Dr. Dunbar has served as principal investigator on federally and privately funded research projects in Tanzania and Zimbabwe. Dr. Dunbar received her M.P.H. and Dr.PH from the University of California, Berkeley (UCB) where she focused on international maternal and child health, and research design and policy evaluation. She also serves as a part time lecturer with UCB in the school of public health.

Ben Plumley, Chief Executive Officer of Pangaea, said, “Dr Dunbar has an outstanding track record in designing and evaluating HIV prevention and care strategies, particularly for women and girls. She will play a crucial role at Pangaea as we strengthen our support to countries in reaching vulnerable groups disproportionately affected by HIV.”

Megan Dunbar said, “I am thrilled to be joining Pangaea at this exciting time in its development. I look forward to working with our country partners and supporters to build targeted HIV programs that make a real, lasting difference in the lives of all people affected by AIDS in developing countries.”

Dr Dunbar’s research and program portfolio has centered on reducing the risk and effects of HIV among women and girls, including orphans and vulnerable children. Her focus has been to develop and evaluate interventions that combine improved educational and economic opportunities with programs designed to encourage gender equity, positive health behaviors and improve access to care and treatment for vulnerable groups.

Pangaea Global AIDS Foundation, which is based in San Francisco, helps countries, heavily affected by HIV, and their international partners, strengthen comprehensive prevention and treatment strategies, with a particular focus on hard-to-reach vulnerable populations, including women and girls, men who have sex with men, injecting drug users and incarcerated populations.

###

Read the full story at http://www.prweb.com/releases/2010/03/prweb3744234.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Heartline(R) Fitness Systems Named to Inc. Magazines Inaugural List of the 5000 Fastest Growing Private Companies in U.S....
2. Allscripts Named to FORTUNE 100 Fastest-Growing Companies List
3. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
4. Karen Vigil Named Senior Vice President and Chief Executive Officer, Blue Shield of Californias Individual, Small Group, and Government Business Unit
5. New Director of Nursing Practice Named for Nurses Association
6. Instrumentation Laboratory Named Top of Class by Respiratory Care Managers
7. Meeting Expectations Named to First Annual CMI 25 List by Corporate Meetings & Incentives Magazine
8. Frances Decker Named Mid-Atlantic Region Sales Executive for AllOne Health Management Solutions
9. Keith Taft Named General Manager of UltraTape Industries
10. AIUM CEO named among most influential in radiology
11. Top Twenty Health Plan Websites Named by TheRatingsGuy.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... , ... April 26, 2017 , ... RawTrition now brings ... way to get nutrients from SUPERFOODS! , RawTrition is taking nutrients to ... cellular level because the body recognizes its raw form (unlike the synthetically made options ...
(Date:4/26/2017)... ... April 26, 2017 , ... MYOLYN, ... to announce that it has received 510(k) clearance from the U.S. Food & ... the MyoCycle Pro. , Both devices are stationary cycling systems that use MYOLYN’s ...
(Date:4/25/2017)... ... April 25, 2017 , ... Coalition Duchenne, ... Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor Therapeutics on ... clinical trial in Duchenne announced today. , Coalition Duchenne funded studies carried ...
(Date:4/25/2017)... ... ... The doctors at Wall Centre Dental are now expanding their practice by accepting ... receive dental care. The doctors offer three treatment options to put victims of ... at their dental office in Vancouver. Wall Centre Dental is currently welcoming even patients ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... unveiling cutting-edge birth defects research related to Zika virus during pregnancy, as well ... society for this important science. , The Teratology Society is ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... 20, 2017  CVS Pharmacy, the retail division ... new store design to enhance the retail customer ... health-focused products and expanded beauty selections paired with ... discover new offerings. Together with its innovative digital ... the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
Breaking Medicine Technology: